Drugs / TritanrixHepB/Hib
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT00866619 Background | Mar 2009 → Mar 2011 | malaria | GlaxoSmithKline | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TritanrixHepB/Hib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00866619 ↗ |
| Modality | Vaccine | “All vaccines have been administered intramuscularly” NCT00866619 ↗ |
| Route | Intramuscular | “administered intramuscularly into the left deltoid.” NCT00866619 ↗ |